[1]刘爱琴,宋子宣.改良视网膜光凝术治疗糖尿病视网膜病变的效果及其对血清血管内皮生长因子和内皮素-1水平的影响[J].新乡医学院学报,2019,36(4):372-375.[doi:10.7683/xxyxyxb.2019.04.018]
　LIU Ai-qin,SONG Zi-xuan.Effect of modified retinal photocoagulation on diabetic retinopathy and its effect on serum vascular endothelial growth factor and endothelin 1 levels[J].Journal of Xinxiang Medical University,2019,36(4):372-375.[doi:10.7683/xxyxyxb.2019.04.018]
点击复制

改良视网膜光凝术治疗糖尿病视网膜病变的效果及其对血清血管内皮生长因子和内皮素-1水平的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年4
页码:
372-375
栏目:
临床研究
出版日期:
2019-04-05

文章信息/Info

Title:
Effect of modified retinal photocoagulation on diabetic retinopathy and its effect on serum vascular endothelial growth factor and endothelin 1 levels
作者:
刘爱琴; 宋子宣
（新乡医学院第三附属医院眼科，河南　新乡　453001）
Author(s):
LIU Ai-qin; SONG Zi-xuan
（Department of Ophthalmology，the Third Affiliated Hospital of Xinxiang Medical University，Xinxiang 453003，Henan Province，China）
关键词:
改良视网膜光凝术; 糖尿病视网膜病变; 血管内皮生长因子; 内皮素-1
Keywords:
modified panretinal photocoagulation; diabetic retinopathy; vascular endothelial growth factor; endothelin 1
分类号:
R587.2R774.1
DOI:
10.7683/xxyxyxb.2019.04.018
文献标志码:
A
摘要:
目的　探讨改良视网膜光凝术治疗糖尿病视网膜病变（DR）的效果及其对血清血管内皮生长因子（VEGF）和内皮素-1（ET-1）水平的影响。方法　将新乡医学院第三附属医院2014年5月至2017年1月收治的84例(106眼)DR患者分为对照组和观察组，每组42例(53眼)。对照组患者给予常规全视网膜光凝术，观察组患者给予改良全视网膜光凝术；每周1次，共4次。比较2组患者治疗前及治疗后6个月的最佳矫正视力（BCVA）、眼压、视网膜毛细血管无灌注区消失率、新生血管消退率及血清VEGF、ET-1水平，并观察2组患者的临床疗效。结果　治疗前2组患者BCVA、眼压、眼底情况及血清VEGF、ET-1水平比较差异无统计学意义（P>0.05）。治疗后6个月2组患者BCVA、眼压与治疗前比较差异无统计学意义（P>0.05），且2组患者BCVA、眼压比较差异无统计学意义（P>0.05）。治疗后6个月，观察组患者无灌注区消失率和新生血管消退率高于对照组 （χ2=4.312、4.201，P<0.05）。治疗后6个月，2组患者血清VEGF和ET-1水平低于治疗前（P<0.05），观察组患者血清VEGF和ET-1水平低于对照组 （P<0.05）。对照组和观察组患者治疗总有效率分别为75.47%（40/53）、92.45%（49/53），观察组患者治疗总有效率高于对照组（χ2=4.312，P<0.05）。结论　改良全视网膜光凝术可以降低DR患者血清VEGF和ET-1水平，延缓血管增殖，提高疗效。
Abstract:
Objective　To explore the effect of modified panretinal photocoagulation（MPRP） in treatment of diabetic retinopathy（DR），and its effect on levels of serum vascular endothelial growth factor （VEGF） and endothelin 1 （ET-1）.Methods　Eighty-four patients with 106 eyes of DR admitted to the Third Affiliated Hospital of Xinxiang Medical University from May 2014 to January 2017 were divided into control group and observation group，with 42 patients（53 eyes） in each group.The patients in the observation group were treated with modified panretinal photocoagu lation(MPRP).And the patients in the control group were treated with traditional panretinal photocoagulation（PRP）.Once a week for four times in total.The best corrected visual acuity （BCVA），intraocular pressure，disappearance rate of retinal capillary non-perfusion zone，regression rate of neovascularization，serum levels of VEGF and ET-1 of the two groups were compared between the two groups before and at six months after treatment，and the clinical effects of the two groups were observed.Results　There was no statistically significant differences in the BCVA，intraocular pressure，fundus conditions，serum VEGF and ET-1 levels between the two groups before treatment （P>0.05）.After six months of treatment，there was no statistically significant difference in the BCVA and intraocular pressure between the two groups （P>0.05），and there was no statistically significant difference in BCVA and intraocular pressure between the two groups （P>0.05）.The disappearance rate of non-perfusion area and regression rate of neovascularization in the observation group was higher than that in the control group （χ2=4.312，4.201；P<0.05）.At six months after treatment，the serum levels of VEGF and ET-1 in the two groups were lower than those before treatment （P<0.05），and the serum levels of VEGF and ET-1 in the observation group were lower than those in the control group （P<0.05）.The total effective rate in the control group and the observation group was 75.47% （40/53） and 92.45% （49/53），respectively.The total effective rate in the observation group was higher than that in the control group （χ2=4.312，P<0.05）.Conclusion　MPRP can reduce serum VEGF and ET-1 levels in DR patients，delay vascular proliferation，and improve the efficacy.

参考文献/References:

［1］　WONG T Y，SUN J，KAWASAKI R，et al.Guidelines on diabetic eye care：the international council of ophthalmology recommen-dationsfor screening，follow-up，referral，and treatment based on resource settings［J］.Ophthalmology，2018，125（10）：1608-1622.
［2］　郑志.糖尿病视网膜病变的临床防治、挑战与展望［J］.中华眼底病杂志，2012，28 （3）：209-214.
［3］　陈丹丹，帅天妓，李娟，等.糖尿病视网膜病变微血管神经病变发病机制的研究进展［J］.国际眼科杂志，2018，18（5）：844-846.
［4］　张惠芬.实用糖尿病学［M］.2版.北京：人民卫生出版社，2001：164-171.
［5］　MESSIAS A，FILHO J A，MESSIAS K，et al.Electroretinographic findings associated with panretinal photocoagulation （PRP） versus PRP Plus intravitreal ranibizumab treatment for highi-isk proliferative diabetic retinopathy［J］.Doc Ophthalmol，2012，124 （3）：225-236.
［6］　中华医学会眼科学分会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2014年）［J］.中华眼科杂志，2014，50（11）：851-865.
［7］　董如娇，陈芳，赵霞，等.糖尿病性视网膜病变个性化视网膜光凝术的临床观察［J］.中国实用眼科杂志，2015，33（11）：1261-1264.
［8］　许艳，姚晶磊，陈冬梅，等.改良与传统全视网膜光凝术治疗糖尿病视网膜病变疗效观察［J］.眼科新进展，2017，37 （12）：1178-1181.
［9］　STITT A W，CURTIS T M，CHEN M，et al.The progress in understanding and treatment of diabetic retinopathy［J］.Prog Retin Eye Res，2016，51：156-186.
［10］　KIRBOGA K，OZEC A V，KOSKER M，et al.The association between diabetic relino-pathy and levels of ischemia modified albumin，total thiol，tota1 antioxidant capacity，and total oxidative stress in serum and aqueous humor［J］.J Ophthalmol，2014，2014：820853.
［11］　尹妮，赵帅，朱红娜.康柏西普预处理联合玻璃体切割术治疗增生型糖尿病视网膜病变［J］.眼科新进展，2017，37（8）：770-772.
［12］　周林，姚进.增殖性糖尿病性视网膜病变玻璃体切割术后高眼压的研究［J］.眼科新进展，2015，35（1）：74-77.
［13］　YUN S H，ADELMAN R A.Recent developments in laser treatment of diabetic retinopathy［J］.Middle East Afr J Ophthalmol，2015，22（2）：157-163.
［14］　CHHABLANI J，SAMBHANA S，MATHAI A，et al.Clinical efficacy of navigated panretinal photocoagulation in proliferative diabetic retinopathy［J］.Am J Ophthalmol，2015，159（5）：884-889.
［15］　齐世欣，于建国.改良超全视网膜光凝术治疗高危增殖性糖尿病视网膜病变［J］.国际眼科杂志，2016，16 （7）：1322-1324.

相似文献/References:

[1]柴树洁,孙秀慧,刘向玲.家属参与性延续护理对糖尿病视网膜病变患者玻璃体切割术后治疗依从性及并发症的影响[J].新乡医学院学报,2021,38(1):080.[doi:10.7683/xxyxyxb.2021.01.018]
　CHAI Shujie,SUN Xiuhui,LIU Xiangling.Effect of family′s participatory continuing nursing on treatment compliance and complications of the patients with diabetic retinopathy after vitrectomy[J].Journal of Xinxiang Medical University,2021,38(4):080.[doi:10.7683/xxyxyxb.2021.01.018]
[2]庞　敏,魏　祎,翁孝刚.2型糖尿病视网膜病变危险因素分析[J].新乡医学院学报,2020,37(3):270.[doi:10.7683/xxyxyxb.2020.03.017]
　PANG Min,WEI Yi,WENG Xiaogang.Analysis of risk factors of type 2 diabetic retinopathy[J].Journal of Xinxiang Medical University,2020,37(4):270.[doi:10.7683/xxyxyxb.2020.03.017]
[3]李春艳,朱安泰.糖尿病视网膜病变并发玻璃体积血手术时机选择[J].新乡医学院学报,2018,35(8):731.[doi:10.7683/xxyxyxb.2018.08.021]
　LI Chun-yan,ZHU An-tai.Choice of the operative opportunity for diabetic retinopathy complicated with vitreous hemorrhage[J].Journal of Xinxiang Medical University,2018,35(4):731.[doi:10.7683/xxyxyxb.2018.08.021]

更新日期/Last Update: 2019-04-05